

業主

年度第



The Company is devoted to providing sustainable and stable dividends based on a healthy balance sheet while giving consideration to various factors such as consolidated financial performance, the dividend on equity ratio (DOE)^{*1} and free cash flow. Acquisition of treasury stock may be carried out appropriately after factors such as the market environment and capital efficiency are taken into account.

DOE is an index contributing to shareholder value that encompasses both the dividend payout ratio, which measures the extent to which profits are distributed to shareholders in the form of dividends, and return on equity (ROE)^{*2}, which measures capital efficiency. Also, DOE shows the ratio of dividend to shareholders' equity and thus serves as an index for balance sheet management.

The Company intends to set the interim dividend for the period (at the end of the second quarter) at ¥70 per share (same amount as the previous year), and expects to set the year-end dividend at ¥80 per share (total dividend of ¥150 per share for the year).


^{*1} DOE (Dividend on equity attributable to owners of the parent ratio) =
Total dividend payout / Equity attributable to owners of the parent

Consolidated Financial Results (IFRS)


(Figures are rounded.)

■ Full year ■ Six months ended September 30


Revenue (Billions of yen)




R&D Expenses (Billions of yen)



Operating Profit (Billions of yen)




Profit for the Period (Billions of yen)



This report includes forward-looking statements with respect to plans and forecasts of future results. Please understand that actual performance may differ significantly from these projections.


Revenue from Major Products

Percentage figures indicate the percentage of total sales.



Revenue by Reporting Segment

Percentage figures indicate the percentage of total sales.



R&D expenses of ¥62.8 billion and Group headquarters' management costs and other expenses of ¥4.6 billion are not allocated to reporting segment profits.

Ongoing Research & Development Projects



Development progress since April 2015 is as follows. (As of October 31, 2015)

- **Eisai Submitted Applications to Regulatory Authorities Seeking an Additional Indication for *Halaven* as a Treatment for Soft Tissue Sarcoma**

In October 2015, Eisai submitted applications to regulatory authorities in Japan, the United States and Europe seeking an additional indication for its in-house developed anticancer agent *Halaven* as a treatment for soft tissue sarcoma.

Soft tissue sarcoma is a type of malignant tumors that occur in fat and muscle and so on. As outcomes are poor for patients with advanced disease, it remains a disease with significant unmet medical needs.

The U.S. Food and Drug Administration (FDA) has granted Priority Review Status to the supplemental New Drug Application (sNDA) for *Halaven*, thereby shortening the review period to six months.

• **Eisai Supporting Efforts to Eliminate Lymphatic Filariasis in Indonesia**

In October 2015, employees including those of Eisai's subsidiary in Indonesia attended an event held in Bogor for mass drug administration (MDA) of people in an endemic area for lymphatic filariasis.

A neglected tropical disease, lymphatic filariasis is transmitted to humans by the bite of a mosquito. The disease, which is painful and can cause disfigurement to parts of the body, is commonly known as elephantiasis. Lymphatic filariasis has gained recognition through the decision in October 2015 to award the Nobel Prize in Physiology or Medicine to Satoshi Omura, a distinguished emeritus professor of Kitasato University, for his discovery of a drug for treating this and other diseases.

Working through the World Health Organization (WHO), the Eisai Group is undertaking an initiative to provide 2.2 billion DEC* tablets, produced at its Vizag Plant in India, free of charge to 250 million people by 2020. The Group provided around 150 million tablets free of charge for MDA in Indonesia in 2015.

*diethylcarbamazine citrate (lymphatic filariasis treatment)

• **Anticancer Agent *Lenvima* Receives Breakthrough Therapy Designation**

In July 2015, Eisai's U.S. subsidiary, Eisai Inc., received a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its in-house developed novel anticancer agent *Lenvima* for the potential indication of advanced and/or metastatic renal cell carcinoma.

The Breakthrough Therapy designation is a program intended to expedite development and review of drugs for serious or life-threatening conditions. The benefits of this designation include more intensive guidance on an efficient drug development program and submission strategy, as well as eligibility for rolling review.

As the figure below shows, *Lenvima* works by blocking signals for tumor cells to grow or to create blood vessels needed to receive oxygen and nutrients. Thus, this innovative molecular targeted anticancer agent starves out cancer cells.

• **Established Newly Consolidated Subsidiary "EA Pharma Co., Ltd." Aiming to become Japan's Largest Gastrointestinal Specialty Pharma**

In October 2015, Eisai and Ajinomoto Co., Inc., signed an integration agreement concerning the splitting off of a portion of Eisai's gastrointestinal disease treatment business and its subsequent succession by Ajinomoto Co.'s wholly-owned subsidiary AJINOMOTO PHARMACEUTICALS CO., LTD., via an absorption-type split. The trade name for the new integrated company will be "EA Pharma Co., Ltd." Eisai will hold 60% of the shares, while Ajinomoto Co. will hold the remaining 40%. The new company, which is slated to commence operations in April 2016, will be one of Eisai's consolidated subsidiaries.

EA Pharma will combine knowledge, know-g A opyS1sai'g 4nI proliferation of tumor cells

